As a former associate professor of medicinal chemistry at the University of Washington, along with her more than 15 years of patent experience, Patricia Campbell provides impactful counseling to clients in all aspects of patent portfolio development in the pharmaceutical and biotechnology sectors, including small molecule pharmaceuticals, antibodies and antibody-drug conjugates, antisense oligonucleotides, diagnostics, enzyme replacements, and machine learning/in silico screening methods for drug identification and development. She has prosecuted some of the most valuable patent portfolios covering approved products from several of the world's premier biotechnology/pharmaceutical companies, including BRINEURA®, EXONDYS 51®, FIRDAPSE®, IDHIFA®, ISTODAX®, KUVAN®, OXBRYTA®, PALYNZIQ®, POMALYST®, REVLIMID®, TALZENNA®, TYZEKA®, VANFLYTA®, VENCLEXTA®, XYREM®, and XYWAV®.
In addition to patent procurement and portfolio management, Patricia advises clients regarding patentability, patent term extensions, Orange Book listing, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios for possible investment, licensing, or acquisition. She also has experience with inter partes review proceedings and oppositions before the European Patent Office. Her representative life sciences clients include AbbVie, BioMarin Pharmaceutical, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Merck, NGM Biopharmaceuticals, Jazz Pharmaceuticals, and Takeda, as well as other start-up companies, established companies, academic institutions, and investment firms.
During her time as a tenured associate professor in the Department of Medicinal Chemistry at the University of Washington, Patricia served as principal investigator on research projects funded by the National Institutes of Health and the Department of Defense. Her research programs included structure-based drug design and mechanistic studies of drug-drug interactions.
Patricia is a member of the American Bar Association and the American Intellectual Property Law Association.
Erfahrung
Weitere Veröffentlichungen
- December 2019
"Artificial Intelligence and the Biopharmaceutical Industry: What's Next?" - February 2019
Patent Eligibility Remains Uncertain — Especially for the Life Sciences — Even After Recent Federal Circuit Decisions and Efforts By the USPTO to Bring Clarity (Part Two of a Two-Part Article) - January 2019
Patent Eligibility Remains Uncertain — Especially for the Life Sciences — Even After Recent Federal Circuit Decisions and Efforts By the USPTO to Bring Clarity (Part One of a Two-Part Article) - Autumn/Winter 2007
Patentable Subject Matter in Biotechnology: Transgenic Animals and Higher Life Forms, Center for Advanced Study & Research on Intellectual Property (CASRIP) Newsletter, Volume 14, Issue 1 - 2007
Cooperative Binding of Acetaminophen and Caffeine within the P450 3A4 Active Site, coauthor, Chem Res Toxicol. 20, 1434-41 - 2006
NMR Studies of Ligand Binding to P450(eryF) Provides Insight into the Mechanism of Cooperativity, coauthor, Biochemistry 45, 1673-84 - 2005
Cooperative Binding of Midazolam with Testosterone and Alpha-Naphthoflavone within the CYP3A4 Ac-tive Site: A NMR T1 Paramagnetic Relaxation Study, coauthor, Biochemistry 44, 14143-51 - 2005
Software Pluralism, Shidler Center for Law, Commerce and Technology at the University of Washington School of Law - 2005
The Thermodynamic Landscape of Testosterone Binding to Cytochrome P450 3A4: Ligand Binding and Spin State Equilibria, coauthor, Biochemistry 44, 1353-66 - 2005
Sites of Covalent Attachment of CYP4 Enzymes to Heme: Evidence for Microheterogeneity of P450 Heme Orientation, coauthor, Biochemistry 44, 13914-20 - 2005
Effects of Repeat Number on the Structure and Dynamics of the Core Peptide Epitope of Cancer Associated MUC1 Mucin: Application to Cancer Vaccine Design, coauthor, Biopolymers 77, 107-20 - 2004
Allosterism in the Elementary Steps of the Cytochrome P450 Reaction Cycle, coauthor, Drug. Met. Rev. 36, 219-30 - 2003
Interaction of a Peptide from the Receptor Binding Domain of Pseudomonas aeruginosa Pili Strain PAK with a Cross-Reactive Antibody: Changes in Backbone Dynamics Induced by Binding, coauthor, Biochemistry 42, 11334-46 - 2003
Probing the Conformational and Dynamical Effects of O-Glycosylation within the Immunodominant Region of a MUC1 Peptide Tumor Antigen, coauthor, J. Peptide Res. 61, 91-108 - 2003
Epitope Mapping of Antigenic MUC1 Peptides to Breast Cancer Antibody Fragment B27.29: A Heteronuclear NMR Study, coauthor, Biochemistry 42, 14293-305 - 2002
Effect of Glycosylation on Core Peptide Epitope Presentation to the Immune System: NMR Studies of MUC1 Glycopeptide-Antibody Interactions, coauthor, Biochemistry 41, 9946-61 - 2001
Structure of a Pilin Monomer from Pseudomonas aeruginosa: Implications for the Assembly of Pili, coauthor, J. Biol. Chem. 276, 24186-93 - 2000
Interaction of a Bacterially Expressed Peptide from the Receptor Binding Domain of Pseudomonas aeruginosa Pili Strain PAK with a Cross-reactive Antibody: Conformation of the Bound Peptide, coauthor, Biochemistry 39, 14847-64 - 2000
Glycosylations versus Conformational Preferences of Cancer Associated Mucin Core, coauthor, Glycoconjugate J. 17, 835-48 - 2000
Backbone Dynamics of a Bacterially Expressed Peptide from the Receptor Binding Domain of Pseudomonas aeruginosa Pili Strain PAK from Heteronuclear 1H-15N NMR Spctroscopy, coauthor, J. Biomol. NMR 17, 239-55 - 1997
Interaction of the Receptor Binding Domains of Pseudomonas aeruginosa Pili Strains PAK, PAO, KB7 and P1 to a Cross-Reactive Antibody and Receptor Analog: Implications for Synthetic Vaccine Design, coauthor, J. Mol. Biol. 267, 382-402 - 1997
Solution Secondary Structure of a Bacterially Expressed Peptide from the Receptor Binding Domain of Pseudomonas aeruginosa Pili Strain PAK: A Heteronuclear Multidimensional NMR Study, coauthor, Biochemistry 36, 12791-801 - 1996
Solution Conformation of an Immunogenic Peptide Derived from the Principal Neutralizing Determinant of the HIV-2 Envelope Glycoprotein gp 125, coauthor, Folding and Design 1, 157-65 - 1996
Lactam Bridge Stabilization of Alpha-helixes: The Role of Hydrophobicity in Controlling Dimeric versus Monomeric Alpha-helices, coauthor, Biochemistry 35, 10041-50 - 1996
NMR Solution Structure of the Receptor Binding Domain of Pseudomonas aeruginosa Pili Strain P1: Identification of a Beta-turn, coauthor, Int. J. Pept. Prote. Res. 48, 539-52 - 1995
A Comparison of NMR Solution Structures of the Receptor Binding Domains of Pseudomonas aeruginosa Pili Strains PAO, KB7 and PAK: Implications for Receptor Binding and Vaccine Design, coauthor, Biochemistry 34, 16255-68 - 1994
High Resolution Structures of Oxidized and Reduced Escherichia coli Thioredoxin, coauthor, Structure 2, 853-68 - 1993
Binding of a High-Energy Substrate Conformer in Antibody Catalysis, coauthor, Proc. Natl. Acad. Sci. USA. 90, 8663-67 - 1993
The Two-Dimensional Transferred Nuclear Overhauser Effect: Theory and Practice, coauthor, Annu. Rev. Biophys. Biomol. Struct. 22, 99-102 - 1991
Interaction of Troponin I and Troponin C: Use of the Two-Dimensional Transferred Nuclear Overhauser Effect to Determine the Structure of the Inhibitory Troponin I Peptide when Bound to Turkey Skeletal Troponin C, coauthor, J. Mol. Biol. 222, 405-21 - 1991
Theoretical Evaluation of the Two-Dimensional Transferred Nuclear Overhauser Effect, coauthor, J. Magn. Reson. 93, 77-92 - 1991
Effects of Internal Motions on the Development of the Two-Dimensional Transferred Nuclear Overhauser Effect, coauthor, J. Biomol. NMR 1, 391-402
- January 18, 2024
Recent Supreme Court Decisions in Intellectual Property, Patricia Campbell & Michael Hendershot; Jones Day University, Silicon Valley Office - January 19, 2023
2022 Patent Law Update, Patricia Campbell & Michael Hendershot; Jones Day University, San Francisco Office - January 19, 2022
AI in Drug Discovery and Development - January 26, 2021
Life Sciences Patent Law Update; Strategies & Practice Tips, Patricia Campbell & Joe Melnik; Jones Day University, Silicon Valley Office - December 2020
Strategies for Protecting AI and other Software-based Technologies in High Tech / Biotech - August 21, 2020
Biopharma AI Patent Portfolio Development Strategies - November 5, 2019
"Prosecuting Antibody Drug Conjugate Inventions: Strategies for Success and Tips from the Trenches" - October 15, 2019
Panelist at Influential Women in IP (WIPR) Conference in San Francisco for two sessions entitled "Women in Leadership: The Issues, Challenges and Solutions" and “Leading Lawyers Share War Stories and Big Win!” - October 12, 2019
"How AI is Transforming the Pharmaceutical and Biotechnology Sectors", ‘From Disruptive Innovations to Real-World Applications’. Chinese Bioscience Association (CBA) Annual Conference - September 17, 2019
"Intellectual Property and Plant - Part II: Plant Genetic Engineering and Industry Trends" - July 27, 2019
"Biotech Meets AI – Potential IP Protection Strategies", Chinese Bioscience Association (CBA) Workshop - May 22, 2019
"The Bayh-Dole Act: Key Developments, Regulatory Changes and Business Considerations Affecting Federally Funded Inventions: Traps, Snares and Best Practices" - March 27, 2019
Intellectual Property and Plants - March 27, 2019
Intellectual Property and Plants – Part I: Plant Patents, Plant Variety Protection Certificates and Utility Patents - January 16, 2019
2018 Patent Law Update, Patricia Campbell & Michael Hendershot; Jones Day University, Silicon Valley Office - January 18, 2019
Women in IP podcast on patent eligibility under 35 U.S.C. § 101 - June 15, 2018
"Introduction to Patents in Biotechnology"; Li Ka Shing Institute of Virology, Edmonton, Canada - May 16, 2018
Women in IP Speaker Series: Developing and Commercializing New Medicines: Do Patents Still Matter? - October 14, 2017
Opportunities for Biosimilar Companies under the U.S. Legal System, 2017 Chinese Bioscience Association Annual Conference - September 6, 2017
Introduction to Careers in Patent Law and Highlights of CRISPR/CAS Dispute; King Hall Intellectual Property Law Association University of California, Davis - April 3, 2017
Patents and Basic Scientific Research: Discovery Versus Invention; 253rd ACS National Meeting and Exposition in San Fransisco, CA Chemistry & the Law (CHAL), "The Use of Scientific Information in IP-Related Matters" - May 26, 2014
The Role of Patents in Biotechnology; "Translational Research Day," Li Ka Shing Applied Virology Institute University of Alberta - May 20, 2013
Introduction to Patent Law II: Stem Cell Patents; Department of Biomedical and General Engineering; California Polytechnic State University - May 7, 2012
Introduction to Patent Law I: Stem Cell Patents; Department of Biomedical and General Engineering; California Polytechnic State University - May 2012
Women in IP Networking Happy Hour
- University of Washington (Seattle) (J.D. 2007); Protein Engineering Network of Centres of Excellence (Edmonton) (Postdoctoral Fellow, 1993-1997); Scripps Research Institute, Department of Molecular Biology (La Jolla, California) (Postdoctoral Fellow, 1992-1993); University of Alberta (Edmonton, Canada) (Ph.D. in Biochemistry 1992); University of British Columbia (Vancouver, Canada) (B.Sc. in Biochemistry and Chemistry with honors 1984)
- California, U.S. District Court for the Northern District of California, and registered to practice before the U.S. Patent and Trademark Office
- French
Bitte beachten Sie vor dem Versenden:
Die Informationen auf unserer Website sind für den allgemeinen Gebrauch und stellen keine Rechtsberatung dar. Der Versand dieser E-Mail ist nicht dazu bestimmt, ein Mandatsverhältnis zu begründen, und der Erhalt dieser E-Mail stellt kein Mandatsverhältnis dar. Alles, was Sie an jemanden in unserer Kanzlei senden, ist nicht vertraulich oder privilegiert, es sei denn, wir haben zugestimmt, Sie zu vertreten. Wenn Sie diese E-Mail versenden, bestätigen Sie, dass Sie diesen Hinweis gelesen und verstanden haben.